Home » Topics » BioWorld Science

BioWorld Science
RSS

Daewoong reports phase IIb topline data on Foistar in mild COVID-19

July 29, 2021

Restoring chondroitin 6-sulfate can rescue age-related memory impairment

July 29, 2021

Clarity initiates phase I/IIa theranostic trial of 64/67Cu SAR-bisPSMA in metastatic CRPC

July 29, 2021

Arcturus cleared to begin phase II study of ARCT-810 for OTC deficiency

July 29, 2021

Venatorx reports phase I data on beta-lactamase inhibitor VNRX-7145

July 29, 2021

New phase Ib/II trial evaluates pembrolizumab combination therapies in second-line ES-SCLC

July 29, 2021

Targeting the IL-8/CXCR2 axis as a potential therapeutic strategy in prostate cancer

July 29, 2021

IDMC of phase II study of EscharEx for venous leg ulcers recommends continuation of trial

July 29, 2021

Selinexor shows antiviral and the anti-inflammatory effects in models of SARS-CoV-2 infection

July 29, 2021

Phase II study of CETP inhibitor obicetrapib meets primary endpoint

July 29, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...